6 results about "Metoprolol" patented technology

The invention discloses an electrochemical sensor, a preparation method thereof, a detection system and application. The preparation method of the electrochemical sensor comprises the following steps: step 1, modifying a glassy carbon electrode with carbon nano onion; step 2, putting the glassy carbon electrode modified in the step 1 into a prepolymerization solution containing metoprolol for cyclic electropolymerization treatment; 3, the glassy carbon electrode treated in the step 2 is placed in a hydrochloric acid solution to be subjected to elution treatment, and the electrochemical sensor is obtained after elution is completed. Aiming at the technical bottleneck of rapid detection of metoprolol, the invention provides the electrochemical sensor, the electrochemical sensor shows excellent selectivity, repeatability and stability on metoprolol, the measurement has a wide linear range, the limit of detection (LOD) value is extremely low, and the electrochemical sensor can be used for detecting the concentration of metoprolol in metoprolol tablets or urine.

The invention discloses a propofol-metoprolol twin drug as well as a preparation method and application thereof, the propofol-metoprolol twin drug is formed by connecting propofol and metoprolol, and the propofol-metoprolol twin drug is named as WSW-E01-166-P. According to the present invention, the WSW-E01-166-P can achieve the deanesthesia effect, and has good drug stability; the compound has relatively high inhibition efficiency on ICa-L, and shows an anti-arrhythmia effect in a barium chloride induced ventricular arrhythmia rat model. The novel twin drug WSW-E01-166-P disclosed by the invention has relatively good performance in the aspects of IVAs resistance, pharmacokinetics, toxicology and the like, and is greatly helpful for later promotion of entering a phase I clinical research process.

Abstract The present invention relates to a method for modulating neuropathies. The method comprises: administering to a subject a therapeutically effective amount of doxazosin, a pharmaceutically acceptable salt or an acceptable form thereof, a therapeutically effective amount of pramipexole, a pharmaceutically acceptable salt or an acceptable form thereof, and a 5 therapeutically effective amount of metoprolol, a pharmaceutically acceptable salt or an acceptable form thereof. Abstract 20 26 20 52 65 03 J ul 2 02 6 A b s t r a c t 2 0 2 6 2 0 5 2 6 5 0 3 J u l 2 0 2 6

This invention belongs to the field of medical data processing technology, and provides a drug risk assessment system and method based on gene polymorphism. The system includes: collecting historical medical data; preprocessing the historical medical data; and filtering features according to specified screening rules; defining positive and negative samples based on the selected features, and establishing a training dataset, specifically including: oversampling a small number of samples before establishing the training dataset to ensure that the number of positive and negative samples is equal; establishing a risk prediction model; training the risk prediction model using the training dataset to obtain a trained risk prediction model; and inputting the drug dosage and test data of the object to be assessed into the trained risk prediction model to obtain the risk assessment result. This invention effectively assesses the risk of metoprolol maintenance dosage.

This invention relates to polymorphs of metoprolol and its salts. Crystal forms and combinations thereof of the free base of metoprolol selected from polymorphs A, B, C, D, E, F, and G are disclosed, as well as crystalline polymorphs of salts of metoprolol. Pharmaceutical compositions containing one or more of these polymorphs and methods for preparing such polymorphs are also disclosed. Metoprolol can be used to treat a variety of diseases associated with low intracellular BH4 levels, such as phenylketonuria.

Provided herein are methods of treating or preventing an arrhythmia in a cardiac graft patient, wherein the method comprises administering combinations of anti-arrhythmic agents (e.g., amiodarone, metoprolol, ivabradine, and / or mexiletine) to the subject in need thereof.